Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Alemtuzumab in the up-front setting

Authors Matthew Kaufman, Kanti R Rai

Published 11 April 2008 Volume 2008:4(2) Pages 459—464

DOI https://doi.org/10.2147/TCRM.S1979

Matthew Kaufman, Kanti R Rai

Long Island Jewish Medical Center, New Hyde Park, NY, USA

Abstract: Alemtuzumab is a humanized chimeric monoclonal antibody targeting CD52. Although this agent already has an important role in the treatment of chronic lymphocytic leukemia (CLL), many of its uses are still being defined. Early trials showed alemtuzumab’s value in refractory disease and helped to define its excellent activity in the bone marrow, spleen and 17p deleted patients. The CAM307 trial has demonstrated alemtuzumab’s efficacy as monotherapy in the front-line setting, and ultimately led to its FDA approval as frontline therapy. Especially promising is the trend toward improved response in patients with high risk cytogenic abnormalities (17p del, 11q del, trisomy 12). The various consolidation trials have also provided promising results of achieving eradication of minimal residual disease (MRD). Although the ultimate benefit of achieving MRD negativity remains under investigation, alemtuzumab’s potent activity on the bone marrow will likely make it an important part of combination therapy.

Keywords: alemtuzumab, chronic lymphocytic leukemia, consolidation, minimal residual disease, 17p deletion, 11q deletion

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Corrigendum

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2013, 9:1-2

Published Date: 27 December 2012

Diagnostic accuracy of dual-source CT angiography and coronary risk stratification

Xia Yang, Lu-yue Gai, Ping Li, et al

Vascular Health and Risk Management 2010, 6:935-941

Published Date: 14 October 2010

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

M Tiseo, M Bartolotti, F Gelsomino, et al

Drug Design, Development and Therapy 2010, 4:81-98

Published Date: 19 May 2010

Integrated care and optimal management of pulmonary arterial hypertension

Geoff Strange, Robin Fowler, Corina Jary, Brad Dalton, Simon Stewart, Eli Gabbay

Journal of Multidisciplinary Healthcare 2009, 2:67-78

Published Date: 12 May 2009

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Therapeutics and Clinical Risk Management 2009, 5:187-207

Published Date: 4 March 2009

Hyaluronic acid gel (Juvéderm™) preparations in the treatment of facial wrinkles and folds

Inja Bogdan Allemann, Leslie Baumann

Clinical Interventions in Aging 2008, 3:629-634

Published Date: 5 December 2008